Evidence map›Paper›PMID 40281011›Full record

ArticleScientific reports2025

Clinical experience of the expanded carrier screening for recessive genetic diseases in a large cohort study in Southern central China.

Lu Pan, Haiyan Luo, Tingting Huang, Huizhen Yuan, Yongyi Zou, Qing Lu, Baitao Zeng, Pengpeng Ma, Yan Yang, Ting Huang and 5 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lu Pan *The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, Jiangxi Province, China.
Haiyan Luo *Jiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Tingting HuangJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Huizhen YuanJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Yongyi ZouJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Qing LuJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Baitao ZengJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Pengpeng MaJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Yan YangJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Ting HuangJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Danping LiuJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Bicheng YangJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China.
Yanqiu LiuJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China. lyq0914@126.com.
Jun ZouJiangxi Maternal and Child Health Hospital, Nanchang, 330006, Jiangxi Province, China. zoujunmb@126.com.
Fen FuThe Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330000, Jiangxi Province, China. fu_fen@163.com.

Funding

Jiangxi Province Key Research and Development Project 20232BBG70023Jiangxi Provincial Natural Science Foundation 20232BAB216025Jiangxi Provincial Science and Technology Plan Projects of Traditional Chinese Medicine 20232B1258
6 · The paper itself

Abstract

Recessive monogenic disorders represent a significant cause of congenital malformations and disabilities in pediatric populations. The present study aims to provide the first comprehensive assessment of clinical experience with expanded carrier screening (ECS) panels in a large cohort from the Jiangxi province of Southern Central China. An ECS panel encompassing 147 genes associated with 155 genetic disorders was initially performed on 5,104 pre-gestational/prenatal females using next-generation sequencing. Following the identification of autosomal recessive conditions in female partners, sequential genetic testing was offered to 1,351 male partners, which included either the same ECS panel or other appropriate genetic tests. Comprehensive reproductive counseling was provided to all the identified at-risk couples (ARCs). Overall, 6,308 participants accepted ECS for 155 conditions (Female: 5,104, Male: 1,204) and approximately 38.43% (2,424/6,308) of them were detected as carriers for at least one of the 155 genetic conditions. The top four prevalent conditions identified in Jiangxi Province were α-thalassemia, GJB2-associated hearing loss, Krabbe disease and Wilson's disease. Among the participated cohort, 1,960 females were identified with AR variants and 1,351 male partners received sequential testing, at a recall rate of 68.93%. Among the tested couples, a total of 36 ARCs (36/1,357, 2.65%) were identified with the same AR (n = 27) or X-linked conditions (n = 9). Our study represents the first large-scale demonstration of the substantial feasibility of ECS in the Jiangxi population of Southern Central China. Based on our findings, we propose that incorporating genes with a carrier frequency threshold of 1/2,000 in the screening panel could serve as an optimal criterion. Our findings may contribute significantly to facilitating future clinical implementations of ECS.

Indexed as

Genes, RecessiveGenetic Carrier ScreeningGenetic Diseases, InbornGenetic TestingAdultChinaCohort StudiesFemaleGenetic CounselingHigh-Throughput Nucleotide SequencingHumansMaleExpanded carrier screeningRecessive conditions, at-risk couplesSouthern Central China

Identifiers

PMID40281011
PMCPMC12032240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.